Evaluation of serum-based cancer biomarkers: A brief review from a clinical and computational viewpoint

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 2, 2015, Pages 103-115

  Yotsukura, Sohiya ^a   Mamitsuka, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Computational evaluation; Diagnostic odds ratio; Likelihood ratios; Predictive values; Quantitative assessment; Receiver operating characteristic curve; Serum biomarkers

Indexed keywords

ALPHA FETOPROTEIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CIRCULATING DNA; CIRCULATING RNA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBRINOGEN DEGRADATION PRODUCT; HAPTOGLOBIN; HEAT SHOCK PROTEIN; HEMOGLOBIN; NUCLEAR MITOTIC APPARATUS PROTEIN; OROSOMUCOID; P2PSA PROTEIN; PREALBUMIN; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN P63; STEM CELL FACTOR RECEPTOR; THYROGLOBULIN; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

AREA UNDER THE CURVE; BLOOD; CYTOPLASM; DIAGNOSTIC ODDS RATIO; DIAGNOSTIC TEST; FALSE POSITIVE RESULT; HUMAN; LIKELIHOOD RATIO; MEASUREMENT; METABOLOMICS; PLASMA; POPULATION SIZE; PREDICTIVE VALUE; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; URINE; ARTIFACT; FEMALE; GENETICS; LABORATORY DIAGNOSIS; MALE; NEOPLASMS; PATHOLOGY; RISK; SAMPLE SIZE; STATISTICAL MODEL;

ANTIGENS, NEOPLASM; AREA UNDER CURVE; ARTIFACTS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; MALE; NEOPLASM PROTEINS; NEOPLASMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; ROC CURVE; SAMPLE SIZE; TUMOR MARKERS, BIOLOGICAL;

EID: 84927137726     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.10.002     Document Type: Review

References (107)

1. Heidenreich A.B.M., Joniau S., Mason M.D., Mottet N., Schmid H.P., et al. Guidelines on prostate cancer. Eur Urol 2008, 53:68-80.
2. McGuire W.L.C.G. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992, 25:1756-1761.
3. Fuzery A.K., Chan L.J., Chan M.M.D.W. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013, 10:13.
4. EP D. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. BMC Med 2012.
5. Pepe M.S.E.R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., Winget M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
6. Kumar M.S.S. Biomarkers of diseases in medicine. Curr Trends Sci 2009, 40:3-17.
7. Drunker E.K.K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J 2013, 4:4-7.
8. Kern S.E. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012, 72:6097-6101.
9. Schröder F.H., Wolters C.H., van den Bergh T., Gosselaar R.C., Bangma C.C.H., et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008, 53:468-477.
10. HB G. Are biomarkers for bladder cancer beneficial?. J Urol 2010, 183:11-12.
11. Xu Y.S.Z., Wiper D.W., Wu M., Morton R.E., Elson P., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280:719-723.
12. EP D. Cancer biomarkers: can we turn recent failures into success?. J Natl Cancer Inst 2010, 102:1462-1467.
13. Baker D.L., Miller M.P.B., et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 2002, 287:3081-3082.
14. Drucker E.K.K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J 2013, 4:7. 10.1186/1878-5085-4-7.
15. Lewington S.B.F., Clarke R. A review on meta-analysis of biomarkers: promises and pitfalls. Clin Chem 2012, 58:1192-1204.
16. Buckler A.J., Ouelette P.D., Danagoulian M., Wernsing J., Suzek G.B.E. A novel knowledge representation framework for the statistical validation of quantitiative imaging biomarkers. J Digit Imaging 2013, 26:614-629.
17. Leman E.S., Trock C.G., Sokoll B.J., Chan L.J., Mangold D.W.L., et al. EPCA-2: a highly specific serum marker for prostate cancer. J Urol 2007, 69:714-720.
18. Li Y.S.Z., Wu Y., Babovic-Vuksanovic D., Li Y., Cunningham J.M., Pankratz V.S., et al. Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk. Lung Cancer 2010, 70:14-21.
19. EP D. Early prostate cancer antigen-2 (EPCA-2): a controversial prostate cancer biomarker?. Clin Chem 2010, 56:542-544.
20. Bohning D.H.H., Patilea V. A limitation of the diagnostic-odds ratio in determining an optimal cut-off value for a continuous diagnostic test. Stat Methods Med Res 2011, 20:541-550.
21. Attia J. Moving Beyond sensitivity and specificity: using likelihood ratios to help interpret diagnostic tests. Aust Prescr 2003, 26:111-113.
22. Grund B.S.S. Analysis of biomarker data: logs, odds ratios and ROC curves. Curr Opin HIV AIDS 2010, 5:473-479.
23. Sonego P., Kocsor A., Pongor S. ROC analysis: applications to the classification of biological sequences and 3D structures. Brief Bioinform 2008, 9:198-209.
24. Warnock D.G.P.C. A roadmap for biomarker qualification. Nat Biotech 2010, 28:444-445.
25. Zheng Y.C.T., Feng Z. Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics 2005, 62:279-287.
26. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
27. Hanley J.A.M.B. The meaning and use of the area under a receiver operating characteristic (ROC) curve. J Radiol 1982, 143:29-36.
28. Grimes D.A.S.K. Making sense of odds and odds ratios. Obstet Gynecol 2008, 111:423-426.
29. Lotrakul M.S.S., Saipanish R. Reliability and validity of the Thai version of the PHQ-9. BMC Psychiatry 1998, 8:46.
30. Jiang W.F.B., Simon R. Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007, 99:1036-1043.
31. Glas A.S.L.J., Prins M.H., Bonsel G.J., Bossuyt P.M.M. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56:1129-1135.
32. Magder L.S.F.A. Optimal choice of a cut point for a quantitative diagnostic test performed for research purposes. J Clin Epidemiol 2003, 56:956-962.
33. Fischer J.E.B.L., Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. J Intensive Care Med 2003, 29:1043-1051.
34. Pepe M.S.F.Z., Huang Y., Longton G., Prentice R., Thompson I.M., Zheng Y. Integrative the predictiveness of a marker with its performance as a classifier. Am J Epidemiol 2007, 167:362-368.
35. Pepe M.S.J.H., Longton G., Leisenring W., Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:82-890.
36. Abraham J. OVA1 test for preoperative assessment of ovarian cancer. Community Oncol 2010, 7:249-251.
37. Ueland F.R.D.C., Seamon L.G., et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011, 117:1289-1297.
38. Chudeka-Glaz AC-PA, Menkiszak J., Sompolska-Rzechula A., Strojna A., Byra E., et al. Preoperative diagnostic performance of ROMA (Risk of Ovarian Malignancy Algorithm) in relation to etiopathogenesis of epithelial ovarian tumors. J Mol Biomark Diagn 2013, S4. 10.4172/2155-9929.S4-003.
39. Montagnana M.D.E., Ruzzenente O., Bresciana V., Nuzzo T., Gelati M., et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful. Clin Chem Lab Med 2011, 49:521-525.
40. Xu E.S.Q., Gu J., Chow W.H., Ajani J.A., Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. Carcinogenesis 2013, 34(11):2521-2524. 10.1093/carcin/bgt230.
41. Chen L.X.J., Riggins R.B., Clarke R., Wang Y. Identifying cancer biomarkers by network-constrained support vector machines. BMC Syst Biol 2011, 5:161-181.
42. Gilligan T. The new data on prostate cancer screening: what should we do now?. Cleve Clin J Med 2009, 76:446-448.
43. Gann P.H.M.J., Catalona W.J., Stampfer M.J. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002, 167:2427-2434.
44. Sterling R.K.J.L., Gordon F., Sherman M., Venook A.P., Reddy K.R. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007, 102:2196-2205.
45. Yuen M.F.L.C. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 2003, 14:1463-1467.
46. Zinkin N.T.G.F., Bhaskar K., Out H.H., Spentzos D., Kalmowitz B., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008.
47. Partheen K.K.B., Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol 2011, 22:244-252.
48. Bozkurt M.Y.A., Aral I. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy. Eur J Gynaecol Oncol 2013, 34:540-544.
49. Okamoto T.O.T., Izuo M., Ito Y., Yamashita T., Tanaka R., et al. Decision making using postoperative CEA and CA 15-3 for detection of breast cancer recurrence. Breast Cancer 1995, 2:127-131.
50. Stieber P., Heinemann V. Tumor markers in metastatic breast cancer: high tumor specificity within the reference range. J Clin Oncol ASCO Annu Meeting Proc 2006, 24:10554.
51. Passerini R.C.M., Boveri S., Salvatici M., Radice D., Zorzino L., et al. The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol 2012, 138:281-287.
52. Gui J.C.Y.W., Liu X.D. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med 2014, 14(2):225-233. 10.1007/s10238-013-0234-9.
53. Ballehaninna U.K., Chamberlain R. Serum CA 19-9 as a Biomarker for panceatic cancer-a comprehensive review. Indian J Surg Oncol 2011, 2:88-100.
54. Cho H.Y.K.K., Jeon T., Kim Y.B., No J.H. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer CA 19-9 level in teratoma. Med Sci Monit 2013, 19:230-235.
55. Roy S.D.A., Kar K. Comparison of urinary and serum CA 19-9 as markers of early stage urothelial carcinoma. Int Braz J Urol 2013, 39:631-638.
56. Lüftner D.M.J., Akrivakis C., Geppert R., Petrides P.E., Wernecke K.D., et al. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000, 20:5077-5082.
57. Barillari P.B.A., Chirletti P., et al. Role of CEA, TPA, and CA 19-9 in the early detection of localized and diffuse recurrent rectal cancer. Dis Colon Rectum 1992, 435:471-476.
58. Palmqvist R.E.B., Lindmark G., Hallmans G., Tavelin B., Nilsson O., et al. Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: a matched case-control study. Dis Colon Rectum 2003, 46:1538-1544.
59. Mahdavi A., Pejovic T., Nezhat F. Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 2006, 85(4):819-826. 10.1016/j.fertnstert.2005.08.061.
60. Gabrielli S.R.R., Pilu G., Pavani A., Capelli M., Milano V., et al. Accuracy of transvaginal ultrasound and serum hCG in the diagnosis of ectopic pregnancy ultrasound. Obstet Gynecol 1992, 2:110-115.
61. Lempiainen A.H.K., Blomqvist C., Alfthan H., Stenman U.H. Hyperglycosylated human chorionic gonadotropin in serum of testicular cancer patients. Clin Chem 2012, 58(7):1123-1129. 10.1373/clinchem.2012.183723.
62. Soyluk O.B.H., Aral F., Alagol F., Özbey N.C. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment. Thyroid 2011, 1301(1308). 10.1089/thy.2011.0122.
63. Baudin E.D.C.C., Cailleux A.F., Leboulleux S., Travagli J.P., Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003, 88:1107-1110.
64. Tan H.X.Y., Xu J., Wang F., Nie S., Yang M., et al. Association of increased heat shock protein 70 levels in the lymphocyte with high risk of adverse pregnancy outcomes in early pregnancy: a nested case-control study. Cell Stress Chaperones 2007, 12:230-236.
65. Shibata T.A.T., Tahara T., Yoshioka D., Maruyama N., Fujita H., Kamiya Y., et al. Protective role of genetic polymorphism of heat shock protein 70-2 for gastric cancer risk. Dig Dis Sci 2009, 54(1):70-74. 10.1007/s10620-008-0313-z.
66. Uozaki H.I.T., Kakiuchi C., Horiuchi H., Gotoh T., Iijima T., et al. Expressiom of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 2000, 196:665-673.
67. Margel DP-FM, Baniel J., Yossepowitch O., Cohen I.R. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur J Urol 2011.
68. King K.L.L.A., Chau G.Y., Chi C.W., Wu C.W., Huang C.L., Lui W.Y. Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 2000, 88(11):2464-2470.
69. Ulivi P.M.L., Casoni G.L., Scarpi E., Bucchi L., Silvestrini R., et al. Multiple marker detection in peripheral blood for NSCLC diagnosis. PLoS One 2013, 8:e57401.
70. Chen C.L.T.H., Liu J.C., Kashiwabara C., Feldman D., Sher L., et al. Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest 2013, 123:2832-2849.
71. González-Santiago AEM-TL, Sánchez-Llamas F., Troyo-Sanromán R., Gurrola-Díaz C.M. TGF-β1 serum concentration as a complementary diagnostic biomarker of lung cancer: establishment of a cut-point value. J Clin Lab Anal 2011, 25(4):238-243. 10.1002/jcla.20465.
72. Slattery M.L.H.J., Lundgreen A., Wolff R.K. Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011, 20(1):57-69. 10.1158/1055-9965.EPI-10-0843.
73. Mose F.N.L., Njunguna R., Tamooh H., John-Stewart G., Farquhar C., Kiarie J. Biomarker evaluation of self-reported condom use among women in HIV-discordant couples. Int J STD AIDS 2013, 24:537-540.
74. Lazzeri M.H.A., Abrate A., de la Taille A., Redorta J.P., McNicholas T., et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Intl 2013, 112:313-321.
75. Yang Z.L.Z., Zhao B., Zhang W., Zhang J., Gi Z., et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cance. Oncol Lett 2013, 6:28-34.
76. Yesil A.B.G., Colak Y., Paker N., Gonen C. Prognostic significance of DR-70 levels in dysplastic colorectal polyps. Gastroenterol Res Pract 2013, 2013:275392. 10.1155/2013/275392.
77. Shabaik A.L.G., Peterson M., Hasteh F., Tipps A., Datnow B., Weidner N. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011, 39:328-332.
78. Deandrea S.T.R., Foschi R., Montella M., Dal Maso L., Falcini F., et al. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study. Cancer Epidemiol Biomarkers Prev 2008, 17:2025-2028.
79. Huang H.J.N.P., Drijkoingen M., Paridaens R., Wildiers H., Van Kimbergen E., et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005, 58:611-616.
80. Sekijima Y.U.S., Tojo K., Sano K., Shimizu Y., Imaeda T., et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 2011, 42:1785-1791.
81. Zhang J.F.P., Liu H., Bai H., Wang Y., Zhang F. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Hum Reprod 2012, 27(8):2484-2493. 10.1093/humrep/des191.
82. Barroso-Sousa R.L.R., Patricia I., Mendonca R., Memoria R.R., Spiller F., et al. Decreased levels of alpha-1-acid glycoprotein are related to the mortality of septic patients in the emergency department. Clinics (Sao Paulo) 2013, 68:1134-1139.
83. Mainous A.G.D.V., Knoll M.E., Hulihan M.M., Grant A.M., Wright R.U. Transferrin saturation and hospital length of stay and mortality in Medicare beneficiaries. J Am Geriatr Soc 2013, 61:132-136.
84. Badoux X.C.K.M., Wang X., O'Biren S.M., Ferrajoli A., Daferl S., et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 2011, 118:2085-2093.
85. Kammerer S.R.R., Hoyal C.R., Reneland R., Marnellos G., Kiechle M., et al. Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility. Proc Natl Acad Sci USA 2005, 102:2004-2009.
86. Soto M.E.B.N., Chineya A.C.P., Rizo H., Telich-Tarriba J.E., Juarez-Orozco L.E., Melendez G., et al. Predictive value of antinuclear antibodies in autoimmune diseases classified by clinical criteria: analytical study in a specialized health institute, 1 year follow-up. Results Immunol 2013, 10.1016/j.rinim.2013.10.003.
87. Joseph B.H.P., Aziz H., Snyder K., Wynne J., Kulvatunyou N., et al. Continuous noninvasive hemoglobin monitor from pulse ox: ready for prime time. World J Surg 2013, 37:525-529.
88. Laudisio A.B.S., Gemma A., Ferrucci L. Antonelli Incalzi R. Metabolic syndrome and hemoglobin levels in elderly adults: the Invecchiare in Chianti Study. J Am Geriatr Soc 2013, 61:963-968.
89. Takahashi Y.N.T., Takeno S., Kimura Y., Okubo M., Kawahara K. Reduced expression of p63 has prognostic implications for patients with esophageal squamous cell carcinoma. Oncol Rep 2006, 15:323-328.
90. Kim T.W.L.H., Kang Y.K., Choe M.S., Ryu M.H., Chang H.M. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004, 10:3076-3081.
91. Meigs J.B.W.K., Sullivan L.M., Hunt K.J., Haffner S.M., Stern M.P. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 2004, 27:1417-1426.
92. Seliger V.I.R.D., Van Goor F., Schmelz A., Mueller P. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 2013, 12:706-713.
93. McWilliams R.R.P.G., Rabe K.G., Holtegaard L.M., Lynch P.J., Bishop M.D., Highsmith E.W. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 2010, 116(1):230-239. 10.1002/cncr.24697.
94. Auewarakul C.U.L.D., Promsuwicha O., Munkhetvit C. C kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia. Ann Hematol 2006, 85:108-112.
95. Nakagawa T.M.S., Goto Y., Koyanagi K., Kitago M., Shingai T., et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 2007, 13(14):4105-4110.
96. Daga H.M.H., Yamamoto N., Shibata T., Endo M., Watanabe H., et al. Small cell lung cancer and other thoracic malignancies: 1519PD Phase II study of Amrubicin in Patients with Refractory or Resistant Rleapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study. Ann Oncol 2012, 23:ix492-ix498.
97. Tang L.Z.S., Wei Liu W., Parchim N.F., Huang J., Tang Y., Gan P., et al. Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer 2013, 13:314. 10.1186/1471-2407-13-314.
98. Jin T., Peng H., Wu H. Clinical value of circulating liver cancer cells for the diagnosis of hepatocellular carcinoma: a meta-analysis. Biomed Rep 2013, 1:731-736.
99. March S., Garcia-Pagan J.C., Masaguer A., Pizcueta P., Bosch J. 529 P-selectin mediates leucocyte rolling in concanavalin-A induced hepatitis. J Hepatol 2004, 40(161):40. 10.1016/S0168-8278(04)90549-1.
100. Msaouel P.K.M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer 2011, 11:336. 10.1186/1471-2407-11-336.
101. Walter R.B.A.F., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119(26):6198-6208. 10.1182/blood-2011-11-325050.
102. Kyrgidis A.T.T., Triaridis S. Melanoma, stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog 2010, 9:3. 10.4103/1477-3163.62141.
103. Saad A.A.R.S., Kanate A., Sebhai A., Merano G., Hobbs G. Correlation among [18-F] FDG-PET/CT, tumor marker CA 27.29, and circulating tumor cells in metastatic breast cancer. J Clin Oncol 2007, 25(suppl):10533.
104. Murakami Y., Toyoda H., Tanahashi T., Tanaka J., Kumada T., et al. Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One 2012, 7(10):e48366. 10.1371/journal.pone.0048366.
105. Sozzi G.C.D., Leon M., Cirincione R., Roz L., Ratcliffe C., Roz E., et al. Quantification of free cirulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003, 21:3902-3908.
106. Douillard J.Y.O.G., Cobo M., Ciuleanu T., McCormack R., Webster A., et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014, 110:55-62.
107. Medeiros L.R.R.D., da Rosa M.I., Bozzetti M.C. Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review. Int J Gynecol Obstet 2009, 142:99-105.